Drugs / RZ-629
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06829563 | Jan → Dec 2025 overdue | type 2 diabetes mellitus | Rezubio Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RZ-629 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06829563 ↗ |
| Route | Oral | “Administered orally” NCT06829563 ↗ |